Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Ocuphire Pharma Inc
OCUP
Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a...
and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:OCUP)
New Post
View:
Posts & Comments
Threaded Posts
(127)
•••
joebravo
X
View Profile
View Bullboard History
Comment by
joebravo
on Sep 27, 2023 8:25am
RE:FDA PDUFA Date September 28, 2023
And there you have it. FDA Approval of Nyxol RM, which will be manufactured and sold under the name RYZUMVI by Viatris starting first half of 2024. Ocuphire will now receive their first
...more
(127)
•••
joebravo
X
View Profile
View Bullboard History
Post by
joebravo
on Sep 13, 2023 8:57am
FDA PDUFA Date September 28, 2023
Not sure why this board has very little following, but this little company with a small float of 21 million shares is about to receive a FDA decision in 2 weeks which could potentially double their
...more
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA
posted Apr 25, 2024 9:00am by
Indiva Ltd
-
|
“Net Income was just shy of break-even in Q4, which is a testament to the popularity of our products, our industry leading low-cost production platform, and our focus on cost control. Our core brands, namely Pearls by Grön, No Future, Bhang Chocolate and Indiva Blips continue to gain market share in Canada, as Indiva continues to hold the #1 market share position in edibles nationally," said ...read more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 24, 2021 10:42am
OCUP....early a.m runner up on NR
You better be looking both ways on this ...... THere is a Shelf Offering on the table This will come back to bite you real hard JMHO
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Feb 14, 2020 11:58am
added more of this one
using dollar cost averaging ,or DCA,for this one,and yes it was a $600 stock but that was 20 years ago,so glta shareholders.
(39)
•••
Teccing
X
View Profile
View Bullboard History
Comment by
Teccing
on Feb 11, 2020 6:16pm
RE:it's a buy today for me
once $600
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Feb 11, 2020 2:52pm
it's a buy today for me
got it this morning at $3.25 per share,it is making a comeback,so glta shareholders.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Stage Set for Creation of a Leading Intermediate Gold Producer
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study